Jaguar Health, Inc. (JAGX)
NASDAQ: JAGX · Real-Time Price · USD
2.570
-0.140 (-5.17%)
Jun 27, 2025, 10:37 AM - Market open
Jaguar Health Revenue
Jaguar Health had revenue of $2.21M in the quarter ending March 31, 2025, a decrease of -5.83%. This brings the company's revenue in the last twelve months to $11.55M, up 13.93% year-over-year. In the year 2024, Jaguar Health had annual revenue of $11.69M with 19.75% growth.
Revenue (ttm)
$11.55M
Revenue Growth
+13.93%
P/S Ratio
0.10
Revenue / Employee
$235,755
Employees
49
Market Cap
3.40M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 11.69M | 1.93M | 19.75% |
| Dec 31, 2023 | 9.76M | -2.20M | -18.36% |
| Dec 31, 2022 | 11.96M | 7.62M | 175.80% |
| Dec 31, 2021 | 4.34M | -5.05M | -53.81% |
| Dec 31, 2020 | 9.39M | 3.61M | 62.51% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
JAGX News
- 1 day ago - Jaguar Health Board of Directors Authorizes Company to Include Cryptocurrency as a Treasury Reserve Asset - Accesswire
- 2 days ago - Jaguar Health to Pursue Approval of Canalevia in European Union for Treatment of General Diarrhea in Dogs - Accesswire
- 2 days ago - Jaguar Health Announces Extension of the Maturity Date of its Convertible Promissory Notes from Recently Closed Bridge Financing to January 30, 2026 - Accesswire
- 4 days ago - Jaguar Health Provides Updates on Orphan Disease Intestinal Failure Development Program for Crofelemer - Accesswire
- 10 days ago - Jaguar Health Presenting June 18 at Emerging Growth Conference to Provide Updates on Near-Term Catalysts - Accesswire
- 16 days ago - First Study Site Established for Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs - Accesswire
- 17 days ago - REMINDER: Jaguar Health to Conduct Fireside Chat 9AM ET June 10 as Part of Lytham Partners' Spring 2025 Spotlight Series - Accesswire
- 18 days ago - Jaguar Health Provides Update on Meeting with FDA Discussing Statistically Significant Results of Responder Analysis of Breast Cancer Patients in Phase 3 OnTarget Trial and Potential Approval Pathway for Crofelemer - Accesswire